Shire
Questcor hires Shire’s chief executive
June 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Questcor, Shire
Biopharma firm Questcor Pharmaceuticals has appointed the recently-retired chief executive of Shire to its Board of directors. Angus Russell …
BMS hires Ann Powell Judge from Shire
February 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ann Powell Judge, BMS, Shire
BMS has announced that Ann Powell Judge will join the company as senior vice president, Human Resources.From March Judge will …
Shire ADHD drug for UK
February 14, 2013Sales and Marketing ADHD, Shire, Vyvanse, elvanse
Shire’s attention-deficit hyperactivity disorder (ADHD) drug Elvanse has been given the go-ahead for use in the UK. Elvanse (lisdexamfetamine dimesylate), …
Shire pays Impax $48 million
February 12, 2013Sales and Marketing ADHD, Adderall, Impax, Shire
Shire has paid $48 million to settle a long-running legal spat with Impax Laboratories over Shire’s supply of an authorised …
Jeff Jonas joins Shire’s Leadership Team
November 15, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jeff Jonas, Shire
Shire has announced that Jeff Jonas has been appointed president of Shire’s Regenerative Medicine (RM) business and will join the …
Shire poaches new head from Bayer
October 26, 2012Sales and Marketing Angus Russell, Flemming Omskov, Shire
Flemming Ornskov, currently chief marketing officer at Bayer, is to take over at Dublin-based Shire Pharmaceuticals next year. He will …
Steven Gillis to join Shire Board of directors
September 19, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Steven Gillis
Shire has announced that Dr Steven Gillis will join the Board of directors in October this year. On joining the …
Shire posts strong quarter results
August 2, 2012Sales and Marketing ADHD, Adderall XR, Pfizer, Q2, Shire, results
Shire has posted a set of healthy financials for the second quarter, buoyed by its ADHD and rare drug portfolio. …
Generic approval for Shire’s hyperactivity drug
June 26, 2012Sales and Marketing ADHD, Adderall XR, FDA, IMS Health, Impax, Shire, Teva
US regulators have delivered a blow to Shire by allowing Actavis Group to produce a generic version of its hyperactivity …
Pfizer Gaucher drug rejected by CHMP
June 25, 2012Sales and Marketing Elelyso, FDA, Gaucher, Pfizer, Shire, Vpriv
A European committee has refused marketing authorisation for Pfizer’s Gaucher disease drug Elelyso, as a competitor drug has exclusivity to …
ABPI: we don’t have the answers for digital yet
June 14, 2012Medical Communications, Sales and Marketing ABPI, Bayer, Deepak Khanna, Shire, digital, online
Pharma’s use of digital media is posing questions that can’t yet be answered, says the new ABPI president Deepak Khanna. …
Shire makes two senior appointments
June 6, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Colpman, Judge, Shire
Shire has announced the promotion of David Colpman and Ann Judge (pictured) as two senior leaders within the firm. Colpman, …
ABPI to help pharma with digital communications
May 4, 2012Medical Communications ABPI, Code breach, PMCPA, Shire, digital, pharma
The ABPI has set up a new group to help pharma with its online communications. The UK industry body said …
Pfizer enters Gaucher disease market
May 3, 2012Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv
Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso. Elelyso (taliglucerase alfa) is an enzyme replacement therapy …
Shire’s Vpriv website in breach of ABPI Code
April 24, 2012Medical Communications, Sales and Marketing ABPI, Genzyme, PMCPA, Shire, Vpriv, code
Shire’s website for its Gaucher’s disease drug Vpriv has fallen foul of the ABPI’s Code of Conduct. The complaint was …
Latest content
